Prescription Drug Monitoring Program (PDMP) LOUISIANA. Information contained in this presentation is accurate as of September 2017

Similar documents
Prescription Drug Monitoring Program (PDMP)

Prescription Drug Monitoring Program (PDMP)

Prescription Monitoring Program:

New Mexico. Contact Information. State Registrant Totals and Population. PDMP name: NM PMP

Massachusetts. Contact Information. State Registrant Totals and Population. PDMP name: MA Prescription Monitoring Program

Prescription Drug Monitoring Program (PDMP)

Mississippi. Contact Information. State Registrant Totals and Population

Ohio. Contact Information. State Registrant Totals and Population

Nevada. Contact Information. State Registrant Totals and Population

Georgia DPH. Prescription Title Drug Heading Monitoring Program Program. Sheila Pierce April 2018

Prescription Monitoring Programs - Legislative Trends and Model Law Revision

Colorado. Contact Information

Tennessee. Tennessee Department of Health, Tennessee Board of Pharmacy Pharmacy Board

Michigan. Contact Information. State Registrant Totals and Population. PDMP name: MAPS

Tennessee. Contact Information. State Registrant Totals and Population. PDMP name: CSMD

2017 ASAP MIDYEAR CONFERENCE THE FUTURE OF PRESCRIPTION DRUG MONITORING PROGRAMS (PMPS): HIGHLIGHTS OF 2017 STATE BILLS JUNE 22, 2017 SHERRY L.

South Carolina Reporting & Identification Prescription Tracking System (SCRIPTS)

Alaska. Contact Information. State Registrant Totals and Population. PDMP name: AKPDMP

NATIONAL ASSOCIATION FOR STATE CONTROLLED SUBSTANCES AUTHORITIES (NASCSA) MODEL PRESCRIPTION MONITORING PROGRAM (PMP) ACT (2016) COMMENT

K-TRACS: Review of Program Data and a Qualitative Assessment Study

CONTINUING MEDICAL EDUCATION OVERVIEW BY STATE

Oklahoma. Contact Information. Office: Fax: Statistics

District of Columbia Prescription Drug Monitoring Program

Puerto Rico. Contact Information. State Registrant Totals and Population. PDMP name: PR PDMP

North Carolina. Contact Information. State Registrant Totals and Population. PDMP region: PDMP name: Agency responsible:

Advanced Nurse Practitioner Supervision Policy

STATE OF TEXAS TEXAS STATE BOARD OF PHARMACY

National Association of Boards of Pharmacy PMP Interconnect NABP

Steps Taken to Combat the Opiate Epidemic Through Legal And Technological Channels. Nick Snyder, Esq.

SENATE, No STATE OF NEW JERSEY. 216th LEGISLATURE INTRODUCED APRIL 28, 2014

The Wisconsin epdmp:

Kentucky. Kentucky Cabinet for Health and Family Services Office of Inspector General

Delegator Dashboard User Guide

Reporting Requirements and Exemptions to Reporting

Prescription Drug Monitoring Programs: Promising Practices to Maximize Their Effectiveness

Practice Advancement Initiative (PAI) Using the ASHP PAI Ambulatory Care Self-Assessment Survey

Summer Webinar Series. The Prescription Drug Monitoring Program (PDMP) Mandate and Where you Fit In June 21, 2018

National Provider Identifier (NPI)

The Challenges of Interstate Data Sharing

Hydrocodone Prescribing and the New Texas PMP

Governor s Office of Electronic Health Information (GOEHI) The National Council for Community Behavioral Healthcare

Prescriber Use of the PDMP: A Statewide Survey and Multistate Focus Groups

Prescription Monitoring Program State Profiles - California

Florida s New Law on Controlled Substance Prescribing

Technical Assistance Guide. Enhancing PDMPs: A Comparison of Changes 2010 to 2016

NCPDP s Recommendations for an Integrated, Interoperable Solution to Ensure Patient Safe Use of Controlled Substances

ASA Survey Results for Commercial Fees Paid for Anesthesia Services payment and practice manaement

Building Blocks to Health Workforce Planning: Data Collection and Analysis

Overview. Appriss Health Substance Use and Opioid Trends NarxCare Overview Live Demo

PRESCRIPTION MONITORING PROGRAM STATE PROFILES TENNESSEE

Policies for TANF Families Served Under the CCDF Child Care Subsidy Program

Pharmacy Law Update for Pharmacists & Technicians October 1, 2017 Greg Baran, B.S., Pharm., M.A.

ASA Survey Results for Commercial Fees Paid for Anesthesia Services payment and practice management

(7) Indicate the appropriate and explicit directions for use. (9) Not authorize any refills for schedule II controlled substances.

Prescription Monitoring Program State Profiles - Illinois

Alaska (AK) Arizona (AZ) Arkansas (AR) California-RN (CA-RN) Colorado (CO)

Other Health Care Providers (Part II) Holly L. Mason, R.Ph., Ph.D. PHRM 831

Legal Issues in Managing Opioid Abuse. Gwen Dayton, JD

Prescription Monitoring Program State Profiles - Michigan

Site-Less CRO Model and esource: Framework for Action

National Committee for Quality Assurance

As Introduced. 131st General Assembly Regular Session H. B. No

Prescription Monitoring Program State Profiles - Pennsylvania

AN ACT. Be it enacted by the General Assembly of the State of Ohio:

Annual Report to the Prescription Drug Monitoring Program Advisory Commission

Evidence-Based Practices to Optimize Prescriber Use of PDMPs

Frequently Asked Questions MN Prescription Monitoring Program (PMP)

Chapter 1: Overview of Texas Pharmacy Law 1 Contact Hour (Mandatory)

Report of the Task Force on Prescription Monitoring Program Standards

DC Board of Pharmacy and Pharmaceutical Control Update

PMIX ADVANCING PMP DATA SHARING THROUGH STANDARDIZATION AND INNOVATION CARL FLANSBAUM, DIRECTOR, NEW MEXICO PMP CO-CHAIR PMIX WORKING GROUP

Objectives: Demonstration of MN PMP RxSentry Reports from workgroups

ASA Survey Results for Commercial Fees Paid for Anesthesia Services practice management

Role of Emergency Responder Registries. Mary E. Clark, JD, MPH Director, Emergency Preparedness Bureau Massachusetts Department of Public Health

States that Allow Prescribers and/or Dispensers to Appoint a Delegate to Access the PMP

Medicaid Innovation Accelerator Program (IAP)

The Journey to Meaningful Use: Where we were, where we are, and where we may be going

Role of e-prescribing in Preventing Opioid Abuse

Prescription Monitoring Program NL. Information for Prescribers and Dispensers

MPN PARTICIPATION AGREEMENT FOR MEDICAL GROUP

State Partnership Performance Measures

Patient-Centered Specialty Practice Readiness Assessment

Medication Assisted Treatment for Opioid Use Disorders Reporting Requirements

Increasing the Workforce Capacity of Health Centers: Reimbursement and Scope of Practice State Policy Report #54

DoD-State Liaison Update NCSL August 2015

NCHIP and NICS Act Grants Overview and Current Status

Missouri Board Of Pharmacy

Upgrading Voter Registration in Florida

Mandatory Electronic Prescribing in NYS

Center for Clinical Standards and Quality /Survey & Certification

Pain Advocacy: A Social Work Perspective THANK YOU! First Things First. Incidence of Pain

Continuing Medical Education Board-by-Board Overview

Massachusetts Prescription Monitoring Program

Disclosures. Learning Objectives. Pharmacy Law Topics. Spring Seminar 2017

Interim Commissioner Lauren A. Smith and Members of the Public Health Council

Report to Congressional Defense Committees

States that Allow Prescribers and/or Dispensers to Appoint a Delegate to Access the PMP

Assuring Better Child Health and Development Initiative (ABCD)

Policies Approved by the 2017 ASHP House of Delegates

Medicaid Managed Care 2012 Fiscal Analysts Seminar August 30, 2012

Transcription:

Prescription Drug Monitoring Program (PDMP) LOUISIANA Information contained in this presentation is accurate as of September 2017

Meet the Speaker Julie W. Breithaupt PharmD, MBA President Louisiana Pharmacists Association 2

What is a Prescription Drug Monitoring Program? A PDMP/PMP is a statewide electronic database which collects designated data on specified substances dispensed to or for patients. The PDMP is housed by a state regulatory, administrative or law enforcement agency. The housing agency disseminates information from the database to individuals who are authorized under state law to receive the information for purposes identified by state law. 3

State PDMP Overview Act 676 of the 2006 LA Legislature authorized the LA Board of Pharmacy to develop, implement, and operate an electronic system for the monitoring of controlled substances and other drugs of concern dispensed in the state or to an address within the state. Goal to improve the state s ability to identify and inhibit the diversion of controlled substances and other drugs of concern in an efficient and cost-effective manner, a manner that shall not impede the appropriate utilization of these drugs for legitimate medical purposes. 4

5 State PDMP Overview

Exceptions/Exclusions for Reporting Veterinarians are excluded. The LA Board of Pharmacy may issue an exemption from the reporting requirements to a dispenser whose practice activities are inconsistent with the intent of the program. The Board will only consider requests from dispensers who do not dispense controlled substances or drugs of concern. 6

Data Exchange Time Period Data must be submitted no later than the next business day after the date of dispensing controlled substances and other drugs of concern (including mail order) Reporting must be submitted to the data collection vendor in approved formats and frequencies. If no applicable substances are dispensed for the preceding reporting period, the pharmacy must file a zero report for that reporting period or be considered non-compliant. 7

Approved Users Prescribers and dispensers of controlled substances and drugs of concern, primarily to their own patients, with the exception of veterinarians. These include physicians, podiatrists, dentists, optometrists, APRNs, PAs, medical psychologists, and every licensed pharmacy. 8

Mandates It is the responsibility of the prescriber/dispenser to be aware of updates/amendments to the legislation as they are enacted and promulgated. June 2017 updates include Requires the prescriber or delegate to access the PMP and review the patient s record prior to issuing the initial prescription for any opioid medication and, in the event the duration of therapy exceeds 90 days, then to access the PMP and review the patient s record every 90 days. Continuing education requirements a minimum of 3 hours relative to drug diversion training, best practice in prescribing of controlled substances, appropriate treatment of addiction, or any similar topic deemed appropriate by the licensing board. 9

Limitations of Matching Data There are clustering algorithms built into the system to assist with patient-matching which are implemented/used by the software vendor. Recommendations for best searches are made available on the website in a Quick Reference Guide. Recommendations are also available in the PMP account for registered users. 10

Data Availability The PMP database for LA is available at https://louisiana.pmpaware.net Authorized users may access only their patients data Individual authorization of the patient is not required under HIPAA, 45CFR Sec 164.512(a)(d). Eligible prescription transactions (Schedules II through V and drugs of concern) are submitted to the Appriss Clearinghouse. Drugs of concern include butalbitalcontaining products that are not controlled. Ephedrine, pseudoephedrine, and phenylpropanolamine-containing products are considered LA Schedule V. 11

Other State Databases The Patient Request (patient search) allows for a search in LA as well as 16 other states: AL, AK, AR, CO, KS, MA, MI, MS, NV, ND, OK, PA, SC, SD, TN, and TX. If a registered user of the PMP Clearinghouse needs to submit data files to an additional state using PMP Aware, the user can submit the request through their account settings page. With recent legislative change facilitating the sharing of data with other states, we continue to identify new states with which we can share prescription data. 12

Analytics MME/Active MME is now available for the prescriber/pharmacist. The registered user may pull a patient s prescription history report w/name, DOB, timeframe Timeframe defaults to most recent 12 months can go back 5 years There is an add-on service for risk scores NARX Care Preparing to turn on interoperability with the electronic health record system of a large health system. 13

Trends and Use Patterns The PMP monitors trends of users and use patterns. An annual report is produced which provides summary data for the operational aspects of the program number of prescription transactions reported to the program database, number of prescribers and dispensers and their delegates registered to access the program data, the number of queries performed by those authorized prescribers, dispensers and delegates, as well as law enforcement agencies and regulatory agencies, and, finally, the average number of queries per day. 14

State PDMP Moving Forward With a recent legislative change facilitating the sharing of data with other states, we continue to identify new states with which we can share prescription data 10-12 states in the next few months Prescriber report cards to be added 15

QIN-QIO Involvement Why work with your QIN-QIO? Access to data Coordinated Efforts QPP Quality Measures & Improvement Activities Ex. Consultation of the PDMP (Activity ID: IA_PSPA_6) Education and training Process Improvement Quality Insights contact Kym Herrin kherrin@eqhs.org Additional QIN-QIO Information: http://qioprogram.org/sites/default/files/ resources/documents/qin- QIO_Fact_Sheet_June2017_508.pdf 16

Thank you for watching! For more information about Louisiana s Prescription Monitoring Program, please contact: Joe Fontenot R.Ph. Assistant Executive Director, Louisiana Board of Pharmacy jfontenot@pharmacy.la.gov 225-922-0094 www.pharmacy.la.gov 17